Adalimumab biosimilar (Jiangsu Zhonghe/Shanghai Junshi/Jiangsu T-Mab)

阿达木单抗生物类似药（江苏众合医药/上海君实生物/江苏泰康生物）

Report date: 2025/12/31 16:42:12

Base Information

Drug NameAdalimumab biosimilar (Jiangsu Zhonghe/Shanghai Junshi/Jiangsu T-Mab)
Drug Alias Name重组人源抗TNF-α单克隆抗体（江苏众合医药）阿达木单抗生物仿制药（苏州众合）君迈康UBP-12119MW0113 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitisCrohn Disease +[7] 
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2022/03/01
Country/TerritoryIndonesiaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Junshi Biosciences Co LtdJiangsu Zhonghe Pharmaceutical Technology Co LtdJiangsu T-Mab Bio-Pharmaceuticals Co Ltd +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Langrun Maiwei Biomedical Technology Co LtdBinnopharm Group LLCShanghai Junshi Biosciences Co Ltd
Inactive CompaniesSuzhou Union Biopharm Biosciences Co LtdJiangsu Zhonghe Pharmaceutical Technology Co Ltd
Active IndicationsPsoriasisUveitisCrohn Disease +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A